Electromed, Inc. has announced its financial results for the third quarter of fiscal year 2025, showing a strong performance marked by growth in key financial metrics. The company's net revenue increased by 13.1% to $15.7 million, compared to $13.9 million in the same quarter of the previous fiscal year. This growth was significantly driven by a 14.8% year-over-year increase in revenue from the direct homecare business, which achieved $14.1 million, up from $12.3 million. The rise in revenues was attributed to more referrals and approvals, improved sales force efficiency, and increased net revenues per approval. Operating income for the quarter rose to $2.1 million, marking a 16.2% increase from the previous year's third quarter. Net income also saw a substantial rise of 26.7%, reaching $1.9 million, or $0.21 per diluted share, compared to $1.5 million, or $0.17 per diluted share, in the prior year. Additionally, Electromed's board of directors approved a $5 million stock repurchase authorization during this quarter. The company also reported an increase in operating cash flow, which reached $7.5 million for the nine months ending in the third quarter of fiscal year 2025, up by $3.0 million from the same period last year. As of March 31, 2025, Electromed had $15.2 million in cash.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。